Levi & Korsinsky is investigating the Board of Directors of Genoptix, Inc. (“Genoptix” or the “Company”) (Nasdaq: GXDX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Novartis. Under the terms of the transaction, Genoptix shareholders will receive $25.00 cash for each share of Genoptix common stock they own, for a total transaction value of approximately $470 million.

Click here to learn how to join the action: http://www.zlk.com/genoptix-gxdx.html, or call: 877-363-5972.

The investigation concerns whether the Genoptix Board of Directors breached their fiduciary duties to Genoptix stockholders by failing to adequately shop the Company before entering into this transaction and whether Novartis is underpaying for Genoptix shares, thus unlawfully harming Genoptix stockholders. In particular, at least one analyst set a price target of $28.00 per share and Genoptix stock traded as high as $38.79 per share as recently as April 30, 2010.

If you own common stock in Genoptix and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/genoptix-gxdx.html.

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major litigations involving mergers and acquisitions. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010